Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1627541.
Leukemia & Lymphoma
Volume 60, 2019 - Issue 13
Letters to the Editor
Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 – azacitidine induces only lymphoma remission
Magnus TobiassonDepartment of Hematology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Correspondence[email protected]
http://orcid.org/0000-0002-3633-5852
http://orcid.org/0000-0002-3633-5852, , , & ![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone
Source:
Wiley-Blackwell
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Source:
American Society of Hematology
Efficacy of 5-Azacytidine in aTET2mutated angioimmunoblastic T cell lymphoma
Source:
Wiley-Blackwell
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Source:
American Society of Hematology
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
Source:
Ferrata Storti Foundation (Haematologica)
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
Source:
Impact Journals, LLC
Efficacy of 5-azacitidine in a TET2 -mutated AITL
Source:
Wiley
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Source:
American Society of Hematology
TET2andDNMT3AMutations in Human T-Cell Lymphoma
Source:
New England Journal of Medicine (NEJM/MMS)
Linking provided by
